Josefin-Beate Holz

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Hans Ulrichts, Karen Silence, Anne Schoolmeester et al. · Blood · 2011 · 178 citations · Full text

Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura

Filip Callewaert, Jan Roodt, Hans Ulrichts et al. · Blood · 2012 · 140 citations

The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura

Josefin-Beate Holz · Transfusion and Apheresis Science · 2012 · 53 citations

Thrombosis, Titan Trial –, Blood Platelet +8

A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance

Timothy A. Yap, Patricia LoRusso, Deborah J. Wong et al. · Clinical Cancer Research · 2022 · 48 citations · Full text

Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions

K. -H. Pfl�ger, Michael Hahn, Josefin-Beate Holz et al. · Cancer Chemotherapy and Pharmacology · 1993 · 42 citations

Pharmacological Study, Pharmacology, Pharmacokinetic Parameters +5